Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Study Assessing Efficacy and Safety of Nivolumab in Italian Patients with Stage IIIB/Stage IV Non-Small-Cell-Lung-Cancer: A Real World Experience

Next Previous
X
Search
Trial Profile

Expanded Access Study Assessing Efficacy and Safety of Nivolumab in Italian Patients with Stage IIIB/Stage IV Non-Small-Cell-Lung-Cancer: A Real World Experience

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Brain metastases; Non-small cell lung cancer; Squamous cell cancer
  • Focus Expanded access; Therapeutic Use

    • Most Recent Events

    • 28 Oct 2019 Results published in the European Journal of Cancer
    • 01 Aug 2019 Preliminary results (n=37 patients with CNS metastases) published in the Anticancer Research
    • 12 Jul 2018 Results of safety and efficacy of nivolumab in a cohort of elderly patients (n=371) published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top